We want to evaluate the utility of statins on heart function according to potency. Patients
with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for
52 weeks. Then we evaluate the effect of pitavastatin and pravastatin primarily on rate of
hospitalization for cardiovascular cause and lipid profile secondarily biomarker,
echocardiography parameter, 6-minute walk, change of NYHA class distribution, cardiovascular
mortality.